AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04586543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2 docetaxel infusion every 3 weeks for maximum of 12 cycles
Study NCT04586543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 docetaxel infusion every 3 weeks for maximum of 12 cycles
Study NCT02266667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2 NEMOST rods : bilateral vertebral-pelvic implantation
Description: Implantation of two NEMOST rods (bilateral vertebral-pelvic implantation)
Study NCT02266667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 NEMOST rod :unilateral vertebral-pelvic implantation
Description: Implantation of one NEMOST rod (unilateral vertebral-pelvic implantation)
Study NCT04171479 — intervention group
Intervention type: DEVICE
Intervention: Epicardial mapping and/or ablation
Description: Either catheter mapping, ablation, or mapping and ablation will be performed using an epicardial catheter approach.
Study NCT01607424 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive remediation
Description: RECOS: cognitive remediation for schizophrenia CRT: cognitive remediation therapy
Study NCT01607424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive remediation
Description: RECOS: cognitive remediation for schizophrenia CRT: cognitive remediation therapy
Study NCT01251848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitaxentan
Description: Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days.
Study NCT01251848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days (morning dose only on Day 5).
Study NCT01251848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Description: Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days
Study NCT01251848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days
Study NCT00253643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea catechin extract
Description: Given orally 2 times/day
Study NCT00253643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil
Description: Given orally 3 times/day
Study NCT00253643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given olive oil placebo orally 3 times/day
Study NCT00253643 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given olive oil placebo orally 3 times/day
Study NCT00253643 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given green tea placebo orally 2 times/day
Study NCT00253643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given green tea placebo orally 2 times/day
Study NCT02462668 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bag-mask ventilation
Description: The control group receives preoxygenation with bag-mask ventilation
Study NCT02462668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation(NIPPV)
Description: The NIPPV group receives noninvasive positive pressure ventilation during fibreoptic bronchoscopy assisted intubation
Study NCT02462668 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: fibreoptic bronchoscopy assisted intubation
Description: All patients will receive fibreoptic bronchoscopy assisted intubation.
Study NCT02462668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fibreoptic bronchoscopy assisted intubation
Description: All patients will receive fibreoptic bronchoscopy assisted intubation.
Study NCT04191330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiovitalsHF
Description: BiovitalsHFTM is a cloud-based platform that incorporates continuous physiology data from remote vital signs monitoring devices and electronic patient reported outcome (ePRO) monitoring of subjects at-home to support GDMT dose titration for HFrEF patients.
Study NCT01778439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-52M51
Study NCT03862352 — intervention group
Intervention type: DEVICE
Intervention: Covered coronary stent
Description: Insertion of covered coronary stent as part of standard care
Study NCT02527369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XP1100RF
Description: Treatment of adipose tissue within the fat layer with XP1100RF device.
Study NCT02710838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: infrared endoscopy
Description: Firstly use standard white light and narrow-band imaging to observe the lesion, and then inject the contrast medium ICG, after 2 minutes,switch to infrared light to observe, record the image data, then accomplish the examination.
Study NCT02710838 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: infrared endoscopy
Description: Firstly use standard white light and narrow-band imaging to observe the lesion, and then inject the contrast medium ICG, after 2 minutes,switch to infrared light to observe, record the image data, then accomplish the examination.
Study NCT01786096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD19A
Description: SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
Study NCT01431196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell vaccination
Description: Autologous dendritic cell vaccination. Dendritic cells are pulsed with their own tumor antigens
Study NCT02779959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Study NCT02779959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochlorperazine
Study NCT00807742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Treatment (NRT)
Description: Nicoderm CQ nicotine skin patch: 21mg patch for 4 weeks, 14mg patch for 2 weeks, 7mg patch for 2 weeks. This is supplemental intervention provided to all.
Study NCT00807742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Treatment (NRT)
Description: Nicoderm CQ nicotine skin patch: 21mg patch for 4 weeks, 14mg patch for 2 weeks, 7mg patch for 2 weeks. This is supplemental intervention provided to all.
Study NCT00807742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Advice
Description: Brief Advice (BA): Patients will receive four sessions of a manualized brief intervention based on NCI guidelines (Manley et al., 1991; Hollis et al., 1993) as modified for sobriety settings. This simple counseling has five components: (1) Assess smoking and initial interest in cessation; (2) Advise the patient to quit smoking; (3) Assist the patient in quitting; (4) Assess interest in quitting; and (5) Arrange booster sessions. This supplemental information is provided to all.
Study NCT00807742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice
Description: Brief Advice (BA): Patients will receive four sessions of a manualized brief intervention based on NCI guidelines (Manley et al., 1991; Hollis et al., 1993) as modified for sobriety settings. This simple counseling has five components: (1) Assess smoking and initial interest in cessation; (2) Advise the patient to quit smoking; (3) Assist the patient in quitting; (4) Assess interest in quitting; and (5) Arrange booster sessions. This supplemental information is provided to all.
Study NCT00807742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Condition provides contingent monetary reinforcement for smoking reductions (first 5 days) then for smoking abstinence (subsequent 14 days). Expired carbon monoxide (CO) levels will be the basis for determining reductions and abstinence.
Study NCT00807742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Contingent Reinforcement
Description: Controls for effects of receiving payments, providing daily breath samples for CO level, and degree of interaction between patient and research staff. NR will allow them to earn an amount which is matched in amount to the expected average earned in CM contingent only on providing breath samples independent of the CO level attained.
Study NCT03339011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational SMS text message
Description: Motivational text messages delivered to the participants' mobile phones. The text messages contain motivational text and advice on physical activity.
Study NCT00873340 — intervention group
Intervention type: DRUG
Intervention: Interferon-1beta (Betaseron, BAY86-5046)
Description: Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be observed.
Study NCT01300169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Collaborative Assessment and Management of Suicidality
Description: Intensive outpatient, suicide-focused, psychotherapy designed to target and treat the drivers of suicidal ideation and behaviors.
Study NCT01300169 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care as Usual
Description: This is just standard outpatient mental health care that is routinely provided in the study site outpatient clinic
Study NCT01241799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound guided fine needle aspiration biopsy
Description: 22 gauge fine needle aspiration biopsy of the pancreatic mass with the stylet in. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the style out is then used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle masses done.
Study NCT01241799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stylet out FNA first, Stylet in FNA second
Description: 22 gauge FNA biopsy of pancreatic mass with the stylet out. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the stylet in is used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle passes done.
Study NCT04149015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel ,oxaliplatin,fluorouracil
Description: A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles.
Study NCT04170439 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clomiphene plus metformin plus N acetyle cysteine in arm number 1
Description: oral adminstration of clomiphene citrate plus metformin plus N acetyl cysteine or chromium
Study NCT04170439 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clomiphene citrate plus metformin with chromium
Description: oral adminstration of clomiphene citrate plus metformin and chromium
Study NCT04170439 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: clomiphene citrate plus metformin
Description: oral adminstration of clomiphene citrate plus metformin
Study NCT02381405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enterade beverage
Study NCT04013529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regret lottery
Description: Subjects who achieve step goals are entered into a lottery in which they can win a financial incentive of $30 or $100.
Study NCT04013529 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Way to Health technology enhanced care
Description: Subjects receive text reminders to reach activity goals.
Study NCT04013529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Way to Health technology enhanced care
Description: Subjects receive text reminders to reach activity goals.
Study NCT03159091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rengalin
Description: Oral administration.
Study NCT03159091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration.
Study NCT02319187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1
Description: S1 80mg to 120 mg per day on Days 1-14, every 21 days
Study NCT02319187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S1 80mg to 120 mg per day on Days 1-10, every 14 days;
Study NCT02319187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: irinotecan 160mg/m2 d1, every 14 days
Study NCT02446431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Avastin is an anti-angiogenic therapy that disrupts a tumor's ability to grow by blocking the vascular endothelial growth factor protein, or VEGF. In tumors, cells produce excess VEGF therefore avastin's ability to block VEGF may prevent the growth of new blood vessels, including normal blood vessels and blood vessels that feed tumors. Avastin is not a chemotherapy; the purpose of Avastin is to block the blood supply that feeds the tumor. In this study Avastin is given IV at 10 mg/kg twice monthly for 10 cycles. This totals 20 administrations over a 1.12 year period.
Study NCT02446431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is an alkylating agent related to nitrogen mustard and is inactive until it is metabolized by P450 isoenzymes (CYP2B6, CYP2C9, and CYP3A4) in the liver to active compounds. The initial product is 4-hydroxycyclophosphamide (4-HC) which is in equilibrium with aldophosphamide which spontaneously releases acrolein to produce phosphoramide mustard. Phosphoramide mustard has been shown to produce interstrand DNA cross-link analogous to those produced by mechlorethamine. The plasma half-life ranges from 4.1 to 16 hours after IV administration. Cytoxan is taken orally as a 25 mg/m2 tablet daily for 14 days for 10 cycles (max dose =50mg). This totals 140 days over a 1.12 year period.
Study NCT02446431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Valproic acid is a short chain fatty acid (VPA, 2-propylpetanoic acid) and approved for the treatment of epilepsy, bipolar disorders, migraines, and clinically used for schizophrenia. Currently, VPA is examined in numerous clinical trials for different leukemias and solid tumor entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. Valproic acid is either given in suspension or tablet form 5 mg/kg, TID for 13 days for 10 cycles. This totals 130 days in a 1.12 year period.
Study NCT02446431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus \[an ester of the immunosuppressive compound sirolimus, (rapamycin, Rapamune®)\] blocks cell cycle progression from the G1 to the S phase by binding to the intracellular cytoplasmic protein, FK506 binding protein (FKBP)12. This complex inhibits activity of the enzyme mTOR (mammalian target of rapamycin), inhibiting translation of several key proteins that regulate progression through the G1 phase in response to growth factors. Sirolimus, the major metabolite of temsirolimus, also binds to FKBP12. Given twice monthly at 25 mg/m2 via IV administration for 10 cycles totalling 20 administrations for 1.12 years.
Study NCT03558984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-PLEX
Description: D-PLEX is a new formulation of extended release of Doxycycline (active ingredient)
Study NCT03558984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The SOC prophylactic antibiotic treatment will be consistent and standardized for all sites in the clinical study. is based on The society of thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice.
Study NCT03558984 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: The SOC prophylactic antibiotic treatment will be consistent and standardized for all sites in the clinical study. is based on The society of thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice.
Study NCT04405687 — intervention group
Intervention type: PROCEDURE
Intervention: Severe head and face deformity reconstructive surgery
Description: Three questionnaires, including the 36-Item Short Form Health Survey questionnaire (SF-36), Aesthetic and Functional Status Score of Facial Soft-Tissue Deformities/Defects (A\&F) and Euroqol 5 dimensions 5 levels questionnaire (EQ-5D-5L), were conducted to evaluate their quality of life and satisfaction with facial aesthetic and functional status.
Study NCT01518218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laying-on-of-hands
Description: The intervention group received laying-on-of-hands every weekday for 1 year along with conventional medicine. The control group did not undergo any alternatives to OPT.
Study NCT02594969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bleach Bath and Moisturizers
Description: All subjects will have one forearm in a bleach bath and the other forearm in a water bath for 10 minutes. Following the bath, skin barrier function will be evaluated. Secondly, moisturizers will be applied to the arms and the skin barrier will be evaluated overtime.
Study NCT02594969 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bleach Bath and Moisturizers
Description: All subjects will have one forearm in a bleach bath and the other forearm in a water bath for 10 minutes. Following the bath, skin barrier function will be evaluated. Secondly, moisturizers will be applied to the arms and the skin barrier will be evaluated overtime.
Study NCT03817554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Pramipexole will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of pramipexole is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
Study NCT03817554 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of placebo is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
Study NCT03817554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of placebo is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
Study NCT04933604 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic partial nephrectomy
Description: Nephron sparing minimally invasive surgery
Study NCT04933604 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic radical nephrectomy
Description: Completely removal of kidney by using laparoscopic surgery
Study NCT02959528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Working memory training
Description: n-back training program
Study NCT02959528 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: perceptual training
Description: visual-perceptual training program
Study NCT04378816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared decision making support tool
Description: Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions.A question prompt list (QPL) is a structured list of questions that serves as a prompt for patients to consider questions to ask their physician.
Study NCT03236220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine
Description: Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine (NAC) (orally at dosages of 400mg 3 times per day). NAC treatment begins from 14 days pre-allotransplant to 2 months after-allotransplant continuously in the absence of disease progression or unacceptable toxicity.
Study NCT04338009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of ARB/ACEI
Description: The randomized intervention will be the discontinuation of ACEI/ARBs. In all participants randomized to discontinuation, treating clinicians will be reminded about the medication discontinuation upon discharge and will be prompted to consider re-initiation of the medication at that time if appropriate, per the clinician's discretion.